SG153666A1 - Treatment of hepatitis b virus infection with human monoclonal antibodies - Google Patents

Treatment of hepatitis b virus infection with human monoclonal antibodies

Info

Publication number
SG153666A1
SG153666A1 SG200702600-8A SG2007026008A SG153666A1 SG 153666 A1 SG153666 A1 SG 153666A1 SG 2007026008 A SG2007026008 A SG 2007026008A SG 153666 A1 SG153666 A1 SG 153666A1
Authority
SG
Singapore
Prior art keywords
hepatitis
treatment
monoclonal antibodies
virus infection
human monoclonal
Prior art date
Application number
SG200702600-8A
Inventor
Shlomo Dagan
Rachel Eren
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to SG200702600-8A priority Critical patent/SG153666A1/en
Publication of SG153666A1 publication Critical patent/SG153666A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a pharmaceutical composition for the treatment or prevention of hepatitis B virus infection, comprising a 1:3 mixture of two fully human anti HBsAg monoclonal antibodies 19.79 and 17.1.41. Also disclosed are preferred modes of administration. The pharmaceutical composition can be given as a monotherapy or in combination with other anti viral agents.
SG200702600-8A 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies SG153666A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG200702600-8A SG153666A1 (en) 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200702600-8A SG153666A1 (en) 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies

Publications (1)

Publication Number Publication Date
SG153666A1 true SG153666A1 (en) 2009-07-29

Family

ID=40901912

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200702600-8A SG153666A1 (en) 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies

Country Status (1)

Country Link
SG (1) SG153666A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047654A1 (en) * 1996-06-11 1997-12-18 Yeda Research And Development Co. Ltd. Human monoclonal antibodies to the hepatitis b surface antigen
WO1997047653A1 (en) * 1996-06-11 1997-12-18 Xtl Biopharmaceuticals Limited Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047654A1 (en) * 1996-06-11 1997-12-18 Yeda Research And Development Co. Ltd. Human monoclonal antibodies to the hepatitis b surface antigen
WO1997047653A1 (en) * 1996-06-11 1997-12-18 Xtl Biopharmaceuticals Limited Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUMAN MONOCLONAL ANTIBO *
PRECLINICAL EVALUATION OF TWO HUMAN ANTI-HEPATITIS B VIRUS (HBV) MONOCLONAL ANTIBODIES IN THE HBV- TRIMERA MOUSE MODEL AND IN HBV CHRONIC CARRIER CHIM *

Similar Documents

Publication Publication Date Title
AP1771A (en) 3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
EE05442B1 (en) A low dose entecavir pharmaceutical composition for the treatment of hepatitis B virus infection and a method for its preparation
BR0111195A (en) Use of b-1,2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection
TW200730537A (en) Methods and compositions for treating hepatitis C virus
HK1068538A1 (en) Antiviral compounds
WO2002032414A3 (en) Ribavirin-pegylated interferon alfa hcv combination therapy
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
MD990258A (en) Method of treatment of the acute viral hepatitis B
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
SG153666A1 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
WO2005016288A3 (en) Methods and compositions for treatment of viral diseases
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2004006848A3 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
DE69706657D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NATURAL HUMAN ALPHA INTERFERON
WO2004067024A3 (en) Hcv combination therapy
WO2003030613A3 (en) Methods of treating liver fibrosis and hepatitis c virus infection
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus
TR200000728T2 (en) The use of IFN-alpha and amantadine in the treatment of chronic hepatitis C.
HK1039935A1 (en) Use of (1r, 4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol in hbv
WO2003006017A3 (en) Use of certain castanospermine esters in the treatment of influenza virus infections
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon